claim: a higher dose, bcg-adjuvanted sars-cov-2 vaccine induces th1-polarized immunity and high-titre neutralizing antibodies in mice
evidence_1: a single dose of bcg:covac was sufficient to induce high-titre sars-cov-2 neutralizing antibodies (nabs) that were detectable as early as 2 weeks post-vaccination; nab levels were greater than that seen in the sera of sars-cov-2-infected individuals.", "this study describes a unique covid-19 vaccine candidate, termed bcg:covac, that when delivered as a single dose induces potent sars-cov-2 specific immunity in mice, particularly through generation of high-titre, anti-viral neutralising antibodies."
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  )